Sanofi's 1st-qtr takes negative currency hit

28 April 2021

Shares of French pharma major Sanofi (Euronext: SAN) edged up 1.7% to 86.84 euros, after the company posted first-quarter 2021 financial results that were hit by currency aspects.

In the first quarter, Sanofi sales were 8.59 billion euros ($10.38 billion), down 4.3% on a reported basis. Exchange rate movements had a negative effect of 6.7 percentage points, mainly driven by the decrease of the US dollar, Brazilian real, Russian rouble, Turkish lira, and Argentine peso and Japanese yen. At constant exchange rates (CER), Sanofi sales increased 2.4%.

First-quarter business operating income (BOI) increased 4.0% to 2.64 billion. At CER, BOI increased 13.3%. The ratio of BOI to net sales increased 2.4 percentage points to 30.7% versus the prior year. Net income was up 14.7% at 2.017 billion euros at CER. Business earnings per share (EPS) were 1.61 euros, up 15% at CER.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK